

FORM 3**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Farrell Michael J.</u> (Last) (First) (Middle) <u>9001 SPECTRUM CENTER BLVD</u> (Street) <u>SAN DIEGO CA 92123</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>03/01/2010</u>	3. Issuer Name and Ticker or Trading Symbol <u>RESMED INC [RMD]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) <u>Sr. Vice President</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>ResMed Common Stock</u>	<u>1</u>	<u>D</u>	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>ResMed NQ Stock Options</u>	<u>02/03/2007⁽¹⁾</u>	<u>02/03/2016</u>	<u>ResMed Common Stock</u>	<u>15,000</u>	<u>38.5</u>	<u>D</u>	
<u>ResMed NQ Stock Options</u>	<u>11/10/2007⁽¹⁾</u>	<u>11/10/2013</u>	<u>ResMed Common Stock</u>	<u>17,000</u>	<u>46.19</u>	<u>D</u>	
<u>ResMed NQ Stock Options</u>	<u>08/01/2008⁽¹⁾</u>	<u>08/01/2014</u>	<u>ResMed Common Stock</u>	<u>25,000</u>	<u>43.42</u>	<u>D</u>	
<u>ResMed NQ Stock Options</u>	<u>11/07/2008⁽¹⁾</u>	<u>11/07/2014</u>	<u>ResMed Common Stock</u>	<u>4,000</u>	<u>42.05</u>	<u>D</u>	
<u>ResMed NQ Stock Options</u>	<u>10/01/2009⁽¹⁾</u>	<u>10/01/2015</u>	<u>ResMed Common Stock</u>	<u>10,000</u>	<u>43.35</u>	<u>D</u>	
<u>ResMed NQ Stock Options</u>	<u>11/20/2009⁽¹⁾</u>	<u>11/20/2015</u>	<u>ResMed Common Stock</u>	<u>55,000</u>	<u>31.04</u>	<u>D</u>	

Explanation of Responses:

1. Options vest 1/4 annually on the anniversary of the grant. Represents date options first became exercisable.

Remarks:

Michael J. Farrell, Sr. Vice
President of Sleep Strategic
Business Unit

03/01/2010

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.